We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
- Authors
Sledge, George W; Neuberg, Donna; Bernardo, Patricia; Ingle, James N; Martino, Silvana; Rowinsky, Eric K; Wood, William C
- Abstract
Between February 1993 and September 1995, 739 patients with metastatic breast cancer were entered on an Intergroup trial (E1193) comparing doxorubicin (60 mg/m(2)), paclitaxel (175 mg/m(2)/24 h), and the combination of doxorubicin and paclitaxel (AT, 50 mg/m(2) and 150 mg/m(2)/24 h, plus granulocyte colony-stimulating factor 5 mg/kg) as first-line therapy. Patients receiving single-agent doxorubicin or paclitaxel were crossed over to the other agent at time of progression.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Vol 21, Issue 4, p588
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2003.08.013